METHOD FOR REMOVING BACTERIA FROM BLOOD USING HIGH FLOW RATE

• US 20170035956A1
• Filed: 10/24/2016
• Published: 02/09/2017
• Est. Priority Date: 04/24/2014
• Status: Abandoned Application

• Current Assignee: ExThera Medical Corporation
• Original Assignee: ExThera Medical Corporation
• Inventors: McCREA, Keith, WARD, Robert
• Application Number:
  US15/332,801
• Publication Number:
  US 20170035956A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: B01J 20/26 Synthetic macromolecular compounds
• CPC Class Codes: B01J 20/28004 Sorbent size or size distribution, e.g. particle size
• CPC Class Codes: B01J 20/28016 Particle form
• CPC Class Codes: B01J 20/28023 Fibres or filaments fibres or filaments in the form of membranes B01J20/28038; B01J20/28007 takes precedence
• CPC Class Codes: B01J 20/3204 Inorganic carriers, supports or substrates
• CPC Class Codes: B01J 20/321 consisting of a polymer obtained by reactions involving only carbon to carbon unsaturated bonds
• CPC Class Codes: B01J 20/3212 consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
• CPC Class Codes: B01J 20/3274 Proteins, nucleic acids, polysaccharides, antibodies or antigens
• CPC Class Codes: B01J 20/3293 Coatings on a core, the core being particle or fiber shaped, e.g. encapsulated particles, coated fibers
• CPC Class Codes: B01J 2220/62 In a cartridge

Abstract

The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates.

Claims

1. An ex vivo method for removing bacteria from a sample taken from a subject who is suspected of being infected with bacteria, the method comprising:

contacting a sample taken from the subject with an adsorption media to allow the formation of an adhering complex, wherein the adhering complex comprises bacteria and the adsorption media; and

separating the sample from the adhering complex to produce the sample with a reduced amount of bacteria.

2. The method of claim 1, wherein the sample is selected from the group consisting of whole blood, serum and plasma.

3. The method of claim 2, wherein the sample is whole blood.

4. The method of claim 1, wherein the adsorption media is a solid substrate of high surface area having a hydrophilic surface that is free of a polysaccharide adsorbent.

5. The method of claim 4, wherein the solid substrate comprises a plurality of rigid polymer bead.

6. The method of claim 5, wherein the rigid polymer bead is a member selected from the group consisting of polyurethane, polymethylmethacrylate, polyethylene or co-polymers of ethylene and other monomers, polyethylene imine, polypropylene, and polyisobutylene.

7. The method of claim 4, wherein the solid substrate comprises one or a plurality of hollow fibers.

8. The method of claim 4, wherein the solid substrate comprises solid fibers or woven yarn made from solid fibers.

9. The method of claim 4, wherein the hydrophilic surface is a cationic surface.

10. The method of claim 1, wherein the adsorption media has a high surface area as a result of surface or roughened topography.

11. The method of claim 4, wherein the hydrophilic surface is a neutrally charged surface.

12. The method of claim 1, wherein the bacteria in the sample is reduced by about 20% to about 99.9%.

13. The method of claim 12, wherein the bacteria in the sample is reduced by about 20% to about 40%.

14. The method of claim 1, wherein the bacteria is a gram-negative bacteria.

15. The method of claim 1, wherein the bacteria is a gram-positive bacteria.

16. The method of claim 1, wherein the bacteria is selected from the group consisting of Escherichia coli, Klebsiella pneumoniae, carbapenem-resistant Escherichia coli, carbapenem-resistant Klebsiella pneumoniae, and extended spectrum beta-lactamase Klebsiella pneumoniae, Enterococcus faecium, Acinetobacter baumannii, and methicillin-resistant Staphylococcus aureus (MRSA).

17. The method of claim 1, wherein the bacteria is selected from the group consisting of Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), and Escherichia coli.

18. An ex vivo method for removing bacteria from a sample taken from a subject who is suspected of being infected with bacteria, wherein the bacteria are known to have a low affinity or no affinity for heparan sulfate, the method comprising:

contacting a sample taken from the subject with an adsorption media to allow the formation of an adhering complex, wherein the adsorption media is a solid substrate of high surface area having at least one polysaccharide adsorbent on the surface thereof; and

separating the sample from the adhering complex to produce the sample with a reduced amount of bacteria.

19. The method of claim 18, wherein the sample is selected from the group consisting of whole blood, serum and plasma.

20. An ex vivo method for removing bacteria from a sample taken from a subject undergoing dialysis, the method comprising:

contacting a sample taken from the subject with an adsorption cartridge comprising adsorption media, wherein the adsorption cartridge is in series with a dialysis cartridge to allow the formation of an adhering complex; and

separating the sample from the adhering complex to produce the sample with a reduced amount of bacteria.